These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 27569835)

  • 41. Serum Concentrations of Leptin and Adiponectin in Dogs with Myxomatous Mitral Valve Disease.
    Kim HS; Kang JH; Jeung EB; Yang MP
    J Vet Intern Med; 2016 Sep; 30(5):1589-1600. PubMed ID: 27573621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
    Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
    J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myxomatous mitral valve disease in the miniature poodle: A retrospective study.
    Meurs KM; Adin D; O'Donnell K; Keene BW; Atkins CE; DeFrancesco T; Tou S
    Vet J; 2019 Feb; 244():94-97. PubMed ID: 30825902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Utility of cardiac MRI to diagnose myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Clark WA; Winter RL; Aarnes TK; Green EM; Mikrut K; Ruz P; Addison D; Rhinehart JD; Schober KE; Friel HT
    Am J Vet Res; 2022 Aug; 83(10):. PubMed ID: 35905145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serotonin concentrations in platelets, plasma, mitral valve leaflet, and left ventricular myocardial tissue in dogs with myxomatous mitral valve disease.
    Cremer SE; Singletary GE; Olsen LH; Wallace K; Häggström J; Ljungvall I; Höglund K; Reynolds CA; Pizzinat N; Oyama MA
    J Vet Intern Med; 2014; 28(5):1534-40. PubMed ID: 25146933
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of standard-dose and high-dose pimobendan on select indices of renal and cardiac function in dogs with American College of Veterinary Internal Medicine stage B2 myxomatous mitral valve disease.
    Kaplan JL; Visser LC; Gunther-Harrington CT; Ontiveros ES; Wittenburg LA; Palm CA; Stern JA
    J Vet Intern Med; 2022 Nov; 36(6):1892-1899. PubMed ID: 36098206
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of 2 loci associated with development of myxomatous mitral valve disease in Cavalier King Charles Spaniels.
    Madsen MB; Olsen LH; Häggström J; Höglund K; Ljungvall I; Falk T; Wess G; Stephenson H; Dukes-McEwan J; Chetboul V; Gouni V; Proschowsky HF; Cirera S; Karlskov-Mortensen P; Fredholm M
    J Hered; 2011; 102 Suppl 1():S62-7. PubMed ID: 21846748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of electrocardiographic parameters in dogs with different stages of myxomatous mitral valve disease.
    Na Y; Lee D; Yun T; Koo Y; Chae Y; Kim H; Yang MP; Kang BT
    Can J Vet Res; 2021 Oct; 85(4):261-270. PubMed ID: 34602730
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anatomic regurgitant orifice area obtained using 3D-echocardiography as an indicator of severity of mitral regurgitation in dogs with myxomatous mitral valve disease.
    Müller S; Menciotti G; Borgarelli M
    J Vet Cardiol; 2017 Oct; 19(5):433-440. PubMed ID: 28964709
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Database development and survival analysis in a clinical and historical cohort of dogs affected by myxomatous mitral valve disease treated or not with pimobendan using causal inference techniques.
    Bagardi M; Palermo V; Locatelli C; Colombo FM; Pazzagli L; Brambilla PG
    Vet Res Commun; 2022 Jun; 46(2):481-486. PubMed ID: 35034282
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration.
    Borgarelli M; Crosara S; Lamb K; Savarino P; La Rosa G; Tarducci A; Haggstrom J
    J Vet Intern Med; 2012; 26(1):69-75. PubMed ID: 22211523
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression Profiling of Circulating MicroRNAs in Canine Myxomatous Mitral Valve Disease.
    Li Q; Freeman LM; Rush JE; Laflamme DP
    Int J Mol Sci; 2015 Jun; 16(6):14098-108. PubMed ID: 26101868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and transforming growth factor-β (TGF-β) in advanced canine myxomatous mitral valve disease.
    Moesgaard SG; Aupperle H; Rajamäki MM; Falk T; Rasmussen CE; Zois NE; Olsen LH
    Res Vet Sci; 2014 Dec; 97(3):560-7. PubMed ID: 25458505
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Right ventricular outflow tract fractional shortening: an echocardiographic index of right ventricular systolic function in dogs with pulmonary hypertension.
    Caivano D; Rishniw M; Birettoni F; Patata V; Giorgi ME; Dei K; Porciello F
    J Vet Cardiol; 2018 Oct; 20(5):354-363. PubMed ID: 30145181
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
    Morita T; Nakamura K; Osuga T; Kawamoto S; Miki S; Sasaoka K; Takiguchi M
    J Vet Cardiol; 2020 Dec; 32():16-27. PubMed ID: 33080489
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of sampling time on urinary electrolytes following oral furosemide administration in dogs with myxomatous mitral valve disease.
    Sabetti MC; Fidanzio F; Troìa R; Perissinotto L; Romito G; Mazzoldi C; Quintavalla C; Crosara S; Dondi F
    J Vet Cardiol; 2022 Jun; 41():57-69. PubMed ID: 35245876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q; Heaney A; Langenfeld-McCoy N; Boler BV; Laflamme DP
    BMC Vet Res; 2019 Nov; 15(1):425. PubMed ID: 31775756
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term effect of granulocyte colony-stimulating factor in dogs with severe myxomatous mitral valve disease.
    Kang MH; Park HM
    Vet Q; 2014; 34(2):60-6. PubMed ID: 25252247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Echocardiographic evaluation of deformity and enlargement of the canine mitral valve annulus associated with myxomatous degenerative mitral valve disease.
    Mihara K; Kanemoto I; Sato K; Yasuhira Y; Watanabe I; Misumi K
    J Vet Cardiol; 2021 Oct; 37():8-17. PubMed ID: 34507141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.